A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Clinical trial NCT03494231 · TERMINATED
Trial details
- NCT number
- NCT03494231
- Sponsor
- Henlix, Inc
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-22
- Primary completion
- 2019-05-17
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.